Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Large Growth · Rbb

Emerald Growth Fund Class C (HSPCX)

Ticker HSPCX · Since 2000-07-01 · · Holdings as of Jul 31, 2026

Expense ratio
1.76%$176/yr per $10k
5-yr return
+7.0%annualized
1-yr return
+29.7%as of Dec 2025
Net assets
$1.5Ball share classes
Holdings
132

Bottom line

Is HSPCX a good fund? The bottom line

HSPCX is the Class C share class of Emerald Growth Fund, an actively managed large growth mutual fund from Rbb.

Its expense ratio is 1.76% — about $176 a year on every $10,000 invested, more expensive than 93% of large growth funds we track.

It returned +29.7% over one year, +7.0% a year over five years, +11.6% a year over ten (as of Dec 31, 2025, per its prospectus).

With $1.5 billion in net assets and 132 holdings, its largest position is F/m Emerald Life Sciences Inno (6.1%) and the top 10 make up 21.4% of the portfolio.

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.76%)
  • 5-year return in the bottom quarter of its category
  • 12b-1 marketing fee of 0.75% a year

Updated Nov 19, 2026

What HSPCX invests in

Emerald Growth Fund (the Fund) seeks long-term growth through capital appreciation.

The Fund has adopted an investment policy that it will, under normal conditions, invest at least 80% of the value of its assets (net assets plus the amount of any borrowings for investment purposes) in equity securities of U.S. and foreign companies, principally common stocks and preferred stocks, identified by the Adviser as having growth characteristics. In identifying investments with growth characteristics, the Adviser utilizes a fundamental approach to choosing securities: the research staff of Emerald conducts company-specific research analysis, taking into account a companys revenue and earnings growth rates and the financial, operating, and market characteristics that distinguish a company from other companies. The Funds policy to invest at least 80% of its assets in such a manner is non-fundamental, which means that it may be changed without shareholder approval. Shareholders…

From the fund's prospectus (filed Sep 8, 2026).

HSPCX performance

Average annual total returns
1 yr5 yr10 yr
HSPCX+29.7%+7.0%+11.6%
Large Growth median+15.2%+11.0%+14.2%

Source: Fund prospectus, as of Dec 31, 2025

Full HSPCX performance history →

What HSPCX costs

On a $10,000 investment, HSPCX's 1.76% expense ratio costs about $176 a year. The prospectus estimates $2,103 in total costs over 10 years (assuming 5% annual returns). The median large growth fund charges 0.87%.

See the full HSPCX fee table →

HSPCX top 10 holdings

#Holding% of fund
1F/m Emerald Life Sciences Inno LFSC6.14%
2U.S. Bank Money Market Deposit Account1.98%
3AAR Corp AIR1.95%
4InterDigital Inc IDCC1.83%
5Travere Therapeutics Inc TVTX1.69%
6VSE Corp VSEC1.68%
7Mercury Systems Inc MRCY1.63%
8Corcept Therapeutics Inc CORT1.54%
9ESCO Technologies Inc ESE1.51%
10Sensient Technologies Corp SXT1.47%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 21.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to HSPCX

More funds like HSPCX →

HSPCX FAQ

What is the expense ratio of HSPCX?
HSPCX's expense ratio is 1.76%, which works out to about $176 a year for every $10,000 invested. The prospectus estimates total costs of $2,103 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HSPCX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.76%); 5-year return in the bottom quarter of its category; 12b-1 marketing fee of 0.75% a year. This is general information, not personalized advice.
What does HSPCX hold?
HSPCX's largest holdings are F/m Emerald Life Sciences Inno (6.1%), U.S. Bank Money Market Deposit Account (2.0%), AAR Corp (1.9%), InterDigital Inc (1.8%), Travere Therapeutics Inc (1.7%). It holds 132 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is HSPCX's 5-year return?
HSPCX returned +7.0% a year over the five years ending Dec 31, 2025, and +11.6% a year over ten years. Past performance does not guarantee future results.
Does HSPCX have a sales load?
No. HSPCX has no front-end sales charge. It may charge a deferred sales charge of up to 1% if sold early.
Who manages HSPCX?
HSPCX is offered by Rbb through Rbb Fund, Inc..